Aktis Oncology

Founded

2020

Former Name

HotKnot Therapeutics, Inc.

Headquarters

Boston, Massachusetts, United States

Stock Ticker

Nasdaq: AKTS

Key Technology

Miniprotein radioconjugate platform

President and CEO

Matthew Roden, PhD

Chief Financial Officer

Kyle Kuvalanka

2020-01-01

2020-04-01

2024-09-30

Aktis Oncology (Nasdaq: AKTS) is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company has developed a proprietary miniprotein radioconjugate platform designed to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors, while being rapidly cleared from normal organs and tissues to minimize systemic radiation exposure. Aktis’ most advanced pipeline program targets Nectin-4, a miniprotein radioconjugate with multi-indication potential across multiple tumor types. The company also maintains a strategic collaboration with Eli Lilly and Company to develop novel anticancer radiopharmaceuticals for [...] 3]; Aktis Oncology (2w): Aktis Oncology is excited to recognize several well-deserved promotions: ▪ Paul Blanchard , Ph.D. has been promoted to Senior Scientist, Lead Discovery. ▪ Victoria Haberman, Ph.D. Haberman has been promoted to Senior Scientist, Chemistry. ▪ Khaled Nasr , Ph.D. has been promoted to Director, Radiopharmaceuticals Development Congratulations, Paul, Victoria and Khaled, and thank you for your commitment to Aktis and the patients we aim to serve! [Likes: 65, Comments: 2]; Aktis Oncology (2w): We’re thrilled to welcome two new members to the Aktis Oncology team: Alicia Deary , Senior Director, Clinical Operations and Nathan Jeon , MSc, Senior Scientist, Radiopharmaceutical Manufacturing. Here are professional highlights about these new team members … and some fun facts, [...] Aktis Oncology (1d): Our President and CEO, Matthew Roden , will give a corporate presentation on 𝗪𝗲𝗱., 𝗝𝘂𝗻𝗲 𝟯, 𝟮𝟬𝟮𝟲 𝗮𝘁 𝟰:𝟮𝟬 𝗽.𝗺. 𝗘𝗧 at the upcoming Jefferies Global Healthcare Conference in NYC. Matt will give an overview of our two clinical-stage programs: 🟦 AKY-1189, a miniprotein radioconjugate targeting Nectin-4 expressing solid tumors 🟦 AKY-2159, a miniprotein radioconjugate targeting B7-H3 expressing solid tumors Matt will also discuss the multiple pillars of value that position Aktis as a next-generation targeted radiopharmaceuticals leader, advancing our vision to expand the reach of this powerful modality to large patient populations with unmet medical needs. 👉Learn more: #Radiopharmaceuticals #RLTs #solidtumors #cancertherapeutics #Nectin4 #B7H3 [Likes: 58, Comments: 0]; Aktis

Aktis Oncology, Inc. is a clinical-stage oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for large patient populations not addressed by existing platform technologies. Aktis' most advanced pipeline program targets Nectin-4, a tumor-associated antigen found in urothelial and other solid cancers. Founded and incubated by MPM BioImpact, Aktis has developed its proprietary miniprotein radioconjugate platform to generate tumor targeting agents with properties ideal for alpha radiopharmaceuticals. Designed to maximize tumor killing through high penetration followed by internalization and retention in cancer cells, Aktis' miniprotein radioconjugates are designed to quickly clear from normal organs and tissues, thereby maximizing anticancer [...] ## Share this article Share this article BOSTON, Sept. 10, 2025 /PRNewswire/ -- Aktis Oncology, Inc., a clinical-stage oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for patient populations not addressed by existing platform technologies, today announced that Matthew Roden, PhD, President and Chief Executive Officer, and other members of the Aktis Oncology leadership team, will participate in the following September investor conferences: | | | --- | | | | | Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit | | | Date: | Thursday, September 11, 2025 | | Location: | New York, N.Y. | | | | Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit Date: [...] To learn more about Aktis Oncology, visit www.aktisoncology.com. Media Contact: Elizabeth Grufferman ICR Healthcare (203) 682-4726 (/cdn-cgi/l/email-protection#9cd9f0f5e6fdfef9e8f4b2dbeee9fafaf9eef1fdf2dcf5ffeef4f9fdf0e8f4fffdeef9b2fff3f1) Investor Contact: Peter Vozzo ICR Healthcare (443) 213-0505 (/cdn-cgi/l/email-protection#b5e5d0c1d0c79be3dacfcfdaf5dcd6c7ddd0d4d9c1ddd6d4c7d09bd6dad8) SOURCE Aktis Oncology ## 21% ### Modal title ## Also from this source AKTIS ONCOLOGY APPOINTS KYLE KUVALANKA CHIEF FINANCIAL OFFICER ### AKTIS ONCOLOGY APPOINTS KYLE KUVALANKA CHIEF FINANCIAL OFFICER Aktis Oncology, Inc., a clinical-stage oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for patient...

Aktis Oncology is a clinical stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors. The company's first of several pipeline programs targets Nectin-4, a tumor-associated antigen found in urothelial and other solid cancers. Founded and incubated by MPM BioImpact, the company has developed its proprietary miniprotein radioconjugate platform to generate tumor targeting agents with properties ideal for alpha radiopharmaceuticals. Designed to maximize tumor killing through high penetration followed by internalization and retention in cancer cells, Aktis's miniprotein radioconjugates quickly clear from other areas of the body, thereby maximizing anticancer activity while minimizing side effects of [...] BOSTON, Sept. 30, 2024 /PRNewswire/ -- Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. The financing was led by RA Capital Management, and co-led by RTW Investments and Janus Henderson Investors. A select syndicate of additional new investors joined the financing, including funds and accounts advised by T. Rowe Price Associates, Inc., Avidity Partners, and an undisclosed life sciences-focused investment fund. All existing institutional investors participated, as well as existing strategic investors Bristol Myers Squibb, Eli Lilly and Company, and MRL [...] anticancer activity while minimizing side effects of treatment. The Aktis platform is isotope-agnostic and further enables clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes. Aktis also has a strategic collaboration with Eli Lilly and Company to leverage its miniprotein platform to develop novel radioconjugates outside of Aktis' proprietary pipeline. To learn more about Aktis Oncology, visit www.aktisoncology.com.

Cookie swap for the holidays 5 / 5 ### About The Company Aktis Oncology, Inc. is a clinical-stage company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Aktis’ most-advanced program, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4, with multi-indication potential across multiple tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, & head and neck cancer. Aktis’ second pipeline program, AKY-2519, is a miniprotein radioconjugate targeting B7-H3 expressing tumors, including prostate, lung and other solid tumors. COMPANY SIZE